Stephen S. Yoder - 24 Feb 2023 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Role
Chief Executive Officer, Director
Signature
/s/ Ahmed Mousa, Attorney-in-fact
Issuer symbol
PVLA
Transactions as of
24 Feb 2023
Net transactions value
$0
Form type
4
Filing time
28 Feb 2023, 16:09:07 UTC
Previous filing
24 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PIRS Stock Option (Right to buy) Award $0 +634,021 $0.000000 634,021 24 Feb 2023 Common Stock 634,021 $1.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.